Brokerages Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Will Announce Earnings of -$0.61 Per Share

Brokerages expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings per share of ($0.61) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.71). Aerie Pharmaceuticals posted earnings of ($0.65) per share in the same quarter last year, which indicates a positive year over year growth rate of 6.2%. The business is expected to issue its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.53) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.42). For the next year, analysts expect that the firm will post earnings of ($1.54) per share, with EPS estimates ranging from ($2.24) to ($0.83). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.02). Aerie Pharmaceuticals had a negative return on equity of 1,531.00% and a negative net margin of 175.35%.

AERI has been the topic of several recent analyst reports. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Monday, July 26th. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Aerie Pharmaceuticals in a research report on Thursday, July 22nd. Needham & Company LLC initiated coverage on Aerie Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $24.00 price target on the stock. Finally, Raymond James set a $15.65 price target on Aerie Pharmaceuticals in a research report on Tuesday, July 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $20.28.

NASDAQ:AERI traded down $0.01 during trading hours on Tuesday, hitting $15.79. 657,474 shares of the company’s stock traded hands, compared to its average volume of 544,992. The firm has a market cap of $745.82 million, a P/E ratio of -4.37 and a beta of 0.72. Aerie Pharmaceuticals has a twelve month low of $9.01 and a twelve month high of $21.30. The company has a debt-to-equity ratio of 8.78, a quick ratio of 2.39 and a current ratio of 2.67. The stock’s fifty day moving average price is $15.11 and its two-hundred day moving average price is $16.74.

A number of hedge funds and other institutional investors have recently modified their holdings of AERI. Envestnet Asset Management Inc. grew its stake in Aerie Pharmaceuticals by 11.8% in the first quarter. Envestnet Asset Management Inc. now owns 70,439 shares of the company’s stock valued at $1,259,000 after purchasing an additional 7,461 shares in the last quarter. M&T Bank Corp grew its stake in Aerie Pharmaceuticals by 12.2% in the first quarter. M&T Bank Corp now owns 12,116 shares of the company’s stock valued at $217,000 after purchasing an additional 1,317 shares in the last quarter. Quantitative Systematic Strategies LLC grew its stake in Aerie Pharmaceuticals by 52.4% in the first quarter. Quantitative Systematic Strategies LLC now owns 31,619 shares of the company’s stock valued at $565,000 after purchasing an additional 10,877 shares in the last quarter. RE Advisers Corp grew its stake in Aerie Pharmaceuticals by 26.7% in the first quarter. RE Advisers Corp now owns 151,638 shares of the company’s stock valued at $2,710,000 after purchasing an additional 32,000 shares in the last quarter. Finally, Swiss National Bank boosted its stake in shares of Aerie Pharmaceuticals by 1.8% during the 1st quarter. Swiss National Bank now owns 91,000 shares of the company’s stock worth $1,626,000 after acquiring an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L.

Further Reading: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.